RU2017132895A - Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента - Google Patents
Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента Download PDFInfo
- Publication number
- RU2017132895A RU2017132895A RU2017132895A RU2017132895A RU2017132895A RU 2017132895 A RU2017132895 A RU 2017132895A RU 2017132895 A RU2017132895 A RU 2017132895A RU 2017132895 A RU2017132895 A RU 2017132895A RU 2017132895 A RU2017132895 A RU 2017132895A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- seq
- pharmaceutical composition
- sirna
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 11
- 201000011510 cancer Diseases 0.000 title claims 8
- 206010028980 Neoplasm Diseases 0.000 title claims 7
- 239000004480 active ingredient Substances 0.000 title claims 5
- 108091070501 miRNA Proteins 0.000 title 1
- 239000002679 microRNA Substances 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 9
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 238000003682 fluorination reaction Methods 0.000 claims 2
- 238000006198 methoxylation reaction Methods 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 108091055411 miR-3670-1 stem-loop Proteins 0.000 claims 2
- 108091039169 miR-3670-2 stem-loop Proteins 0.000 claims 2
- 108091024959 miR-3670-3 stem-loop Proteins 0.000 claims 2
- 108091045722 miR-3670-4 stem-loop Proteins 0.000 claims 2
- 108091086868 miR-4477a stem-loop Proteins 0.000 claims 2
- 108091063295 miR-8078 stem-loop Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000011645 metastatic carcinoma Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Фармацевтическая композиция для лечения рака, которая включает в качестве активного ингредиента одну или несколько миРНК, выбранных из группы, состоящей из miR-3670, miR-8078 и miR-4477a.
2. Фармацевтическая композиция по п. 1, при этом miR-3670 включает в качестве активного ингредиента двухцепочечную РНК, представленную нуклеотидными последовательностями SEQ ID NO: 35 и SEQ ID NO: 36; или SEQ ID NO: 35 и SEQ ID NO: 67.
3. Фармацевтическая композиция по п. 1, при этом miR-4477a включает в качестве активного ингредиента двухцепочечную РНК, представленную нуклеотидными последовательностями SEQ ID NO: 43 и SEQ ID NO: 44; или SEQ ID NO: 43 и SEQ ID NO: 68.
4. Фармацевтическая композиция по п. 1, при этом miR-8078 включает в качестве активного ингредиента двухцепочечную РНК, представленную нуклеотидными последовательностями SEQ ID NO: 65 и SEQ ID NO: 66; или SEQ ID NO: 65 и SEQ ID NO: 69.
5. Фармацевтическая композиция по п. 1, при этом миРНК индуцирует апоптоз раковых клеток при лечении рака.
6. Фармацевтическая композиция по п. 1, при этом рак представляет собой одно или несколько раковых заболеваний, выбранных из группы, состоящей из первичного рака типа рака легких, рака печени, рака желудка, колоректального рака, рака поджелудочной железы, рака желчного пузыря и желчных протоков, рака молочной железы, лейкемии, рака пищевода, неходжкинской лимфомы, рака щитовидной железы, рака шейки матки или рака кожи; метастатической карциномы, возникающей при метастазировании в другие органы из исходного места первичного рака; и неопластических заболеваний, вызванных аномально чрезмерным усилением деления клеток.
7. Фармацевтическая композиция по любому из пп. 1-5, при этом миРНК представляет собой аналог миРНК.
8. Фармацевтическая композиция по п. 7, при этом аналог миРНК выбран из группы, состоящей из таких, которые частично содержат фосфоротиоатную структуру, в которой структура фосфатного остова РНК замещена другим элементом типа серы; таких, у которых РНК полностью или частично заменена молекулой ДНК, ПНК (пептидной нуклеиновой кислоты) или LNA (блокированной нуклеиновой кислоты); и таких, у которых 2′-гидроксильная группа сахара в РНК замещена различными функциональными структурами типа метилирования, метоксилирования или фторирования.
9. Фармацевтическая композиция по п. 7, при этом аналог миРНК состоит из предшественника миРНК в виде при-миРНК или пре-миРНК либо предшественника миРНК в виде плазмиды.
10. Фармацевтическая композиция по п. 9, при этом предшественник миРНК выбран из группы, состоящей из таких, которые частично содержат фосфоротиоатную структуру, в которой структура фосфатного остова РНК замещена другим элементом типа серы; таких, у которых РНК полностью или частично заменена молекулой ДНК, ПНК (пептидной нуклеиновой кислоты) или LNA (блокированной нуклеиновой кислоты); и таких, у которых 2′-гидроксильная группа сахара в РНК замещена различными функциональными структурами типа метилирования, метоксилирования или фторирования.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0026557 | 2015-02-25 | ||
| KR20150026557 | 2015-02-25 | ||
| PCT/KR2016/001828 WO2016137235A2 (ko) | 2015-02-25 | 2016-02-25 | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017132895A true RU2017132895A (ru) | 2019-03-25 |
| RU2017132895A3 RU2017132895A3 (ru) | 2019-03-25 |
| RU2686313C2 RU2686313C2 (ru) | 2019-04-25 |
Family
ID=56789628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017132895A RU2686313C2 (ru) | 2015-02-25 | 2016-02-25 | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10351849B2 (ru) |
| EP (1) | EP3263135B1 (ru) |
| JP (1) | JP6538183B2 (ru) |
| KR (2) | KR101862080B1 (ru) |
| CN (2) | CN107454843B (ru) |
| AU (1) | AU2016224201B2 (ru) |
| BR (1) | BR112017018318A2 (ru) |
| CA (2) | CA2977624C (ru) |
| RU (1) | RU2686313C2 (ru) |
| WO (1) | WO2016137235A2 (ru) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102557689B1 (ko) | 2014-06-12 | 2023-07-20 | 국립연구개발법인 고쿠리츠간켄큐센터 | 전립선암 검출 키트 또는 디바이스 및 검출 방법 |
| KR101861738B1 (ko) * | 2016-08-24 | 2018-05-29 | (주)바이오니아 | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |
| CN107058474B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒 |
| KR20180075139A (ko) | 2016-12-26 | 2018-07-04 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
| US20210139895A1 (en) * | 2017-06-16 | 2021-05-13 | Prostemics Co., Ltd. | Pharmaceutical composition for preventing or treating cancer |
| US11311568B2 (en) | 2017-11-09 | 2022-04-26 | Purmx Therapeutics, Inc. | Therapeutic pharmaceutical composition for cancer including miRNA |
| KR102189987B1 (ko) * | 2017-11-27 | 2020-12-11 | (주)프로스테믹스 | miRNA를 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
| WO2019103581A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |
| WO2019103300A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | Mirna를 포함하는 상처 치료 또는 피부 개선용 조성물 |
| WO2019103578A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN107881237B (zh) * | 2017-12-01 | 2020-11-20 | 唐山市人民医院 | 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用 |
| KR102141124B1 (ko) | 2018-01-30 | 2020-08-04 | (주)바이오니아 | 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도 |
| US10987428B2 (en) * | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
| JP7378739B2 (ja) | 2018-08-10 | 2023-11-14 | 東レ株式会社 | 前立腺がんの検出のためのキット、デバイス及び方法 |
| KR102178919B1 (ko) * | 2018-11-26 | 2020-11-13 | 순천향대학교 산학협력단 | 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도 |
| KR102133205B1 (ko) | 2018-12-05 | 2020-07-13 | 충북대학교 산학협력단 | PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102418779B1 (ko) * | 2018-12-12 | 2022-07-08 | (주)프로스테믹스 | 신규한 miRNA 유사체 및 이의 용도 |
| JPWO2020235671A1 (ru) * | 2019-05-23 | 2020-11-26 | ||
| CN110184338B (zh) * | 2019-05-31 | 2023-04-07 | 南方医科大学第三附属医院（广东省骨科研究院） | 脑脊液外泌体miRNA在MMD诊断和治疗中的应用 |
| US20220241315A1 (en) | 2019-06-05 | 2022-08-04 | Cancerstem Tech Inc. | Therapeutic agent for cancer |
| KR102085260B1 (ko) | 2019-06-19 | 2020-03-05 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
| CN110607368B (zh) * | 2019-09-19 | 2021-07-13 | 西安交通大学 | miRNA3926-1基因作为胰腺癌诊断和疗效标志物的应用 |
| CN111467504A (zh) * | 2020-03-13 | 2020-07-31 | 南方医科大学 | miR-4469在制备抗结直肠癌药物中的应用 |
| CN111349704B (zh) * | 2020-03-17 | 2020-11-24 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
| CN111466339A (zh) * | 2020-04-02 | 2020-07-31 | 华北理工大学 | miRNA-203a-3p在促进胰腺癌细胞增殖和迁移中的应用 |
| CN111387143A (zh) * | 2020-04-02 | 2020-07-10 | 华北理工大学 | miRNA-203a-3p在开发抑制胰腺癌药物中的应用 |
| US20230407401A1 (en) * | 2020-05-29 | 2023-12-21 | National Institute Of Immunology | Dna damage dependent microrna signature for cancers, methods and uses related thereto |
| CN114058698B (zh) * | 2020-07-29 | 2023-08-15 | 四川大学华西医院 | 检测外泌体miR-6879-5p的试剂在制备甲状腺癌转移检测试剂盒中的用途 |
| CN114058697B (zh) * | 2020-07-29 | 2023-08-18 | 四川大学华西医院 | 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途 |
| US20220119812A1 (en) * | 2020-10-20 | 2022-04-21 | Duquesne University Of The Holy Spirit | Micro rna interactions as therapeutic targets for covid-19 and other viral infections |
| CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
| CA3206861A1 (en) * | 2021-02-25 | 2022-09-01 | Han-Oh Park | Composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded mirna as active ingredient |
| CN113041255B (zh) * | 2021-04-13 | 2022-10-11 | 上海中医药大学 | 一种新发现miRNA–mRNA调控轴介导肺腺癌NCI-H1299细胞焦亡的方法 |
| CN113981074A (zh) * | 2021-12-10 | 2022-01-28 | 石河子大学 | 一种与2型糖尿病相关的microRNA及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US15071A (en) * | 1856-06-10 | John h | ||
| CA2604288C (en) * | 2005-04-12 | 2021-07-06 | Universite Libre De Bruxelles | Use of a galectin-1-targeted rnai-based approach for the treatment of cancer |
| CA2689974A1 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| KR101325186B1 (ko) * | 2008-01-23 | 2013-11-07 | (주)바이오니아 | 이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제 |
| AU2008354754B2 (en) | 2008-04-17 | 2014-09-11 | The Johns Hopkins University | On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors |
| US20120302626A1 (en) | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
| EP2681336A4 (en) * | 2011-03-02 | 2014-11-19 | Groove Biopharma Corp | ENHANCED BIODISTRIBUTION OF OLIGOMERS |
| CN103505743A (zh) * | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | 含功能性microRNA/siRNA的细胞微粒子及其应用 |
| EP2900822B1 (en) | 2012-09-26 | 2021-11-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligomers with improved off-target profile |
| EP2919817A4 (en) | 2012-11-16 | 2016-10-19 | Univ Texas | MIARN AS NEW THERAPEUTIC ADJUVANTS AND BIOMARKERS OF THE PROGNOSIS AND TREATMENT OF CHEMORESISTING BREAST CANCER |
| WO2014100252A1 (en) * | 2012-12-18 | 2014-06-26 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate rna processing |
| CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
-
2016
- 2016-02-25 AU AU2016224201A patent/AU2016224201B2/en not_active Ceased
- 2016-02-25 CA CA2977624A patent/CA2977624C/en active Active
- 2016-02-25 CN CN201680018165.9A patent/CN107454843B/zh not_active Expired - Fee Related
- 2016-02-25 US US15/553,097 patent/US10351849B2/en not_active Expired - Fee Related
- 2016-02-25 BR BR112017018318-8A patent/BR112017018318A2/pt not_active IP Right Cessation
- 2016-02-25 EP EP16755885.7A patent/EP3263135B1/en active Active
- 2016-02-25 CA CA3134991A patent/CA3134991A1/en not_active Abandoned
- 2016-02-25 RU RU2017132895A patent/RU2686313C2/ru active
- 2016-02-25 CN CN202110786758.2A patent/CN113633656A/zh active Pending
- 2016-02-25 JP JP2017545217A patent/JP6538183B2/ja not_active Expired - Fee Related
- 2016-02-25 KR KR1020160022462A patent/KR101862080B1/ko active IP Right Grant
- 2016-02-25 WO PCT/KR2016/001828 patent/WO2016137235A2/ko active Application Filing
-
2018
- 2018-05-15 KR KR1020180055329A patent/KR101960067B1/ko active IP Right Grant
-
2019
- 2019-03-31 US US16/371,026 patent/US10612026B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2977624C (en) | 2021-11-30 |
| EP3263135A4 (en) | 2018-09-19 |
| WO2016137235A3 (ko) | 2016-10-20 |
| EP3263135A2 (en) | 2018-01-03 |
| KR20160103949A (ko) | 2016-09-02 |
| KR101960067B1 (ko) | 2019-03-20 |
| US10351849B2 (en) | 2019-07-16 |
| KR101862080B1 (ko) | 2018-07-04 |
| AU2016224201A1 (en) | 2017-09-21 |
| US20190218555A1 (en) | 2019-07-18 |
| JP2018507866A (ja) | 2018-03-22 |
| CN107454843B (zh) | 2021-07-30 |
| CN107454843A (zh) | 2017-12-08 |
| US10612026B2 (en) | 2020-04-07 |
| KR20180054549A (ko) | 2018-05-24 |
| RU2017132895A3 (ru) | 2019-03-25 |
| RU2686313C2 (ru) | 2019-04-25 |
| WO2016137235A9 (ko) | 2016-11-24 |
| US20180030440A1 (en) | 2018-02-01 |
| JP6538183B2 (ja) | 2019-07-03 |
| CN113633656A (zh) | 2021-11-12 |
| EP3263135B1 (en) | 2020-01-15 |
| AU2016224201B2 (en) | 2018-07-05 |
| WO2016137235A2 (ko) | 2016-09-01 |
| BR112017018318A2 (pt) | 2018-07-10 |
| CA2977624A1 (en) | 2016-09-01 |
| CA3134991A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017132895A (ru) | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента | |
| Nadiminty et al. | MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth | |
| JP2018512110A5 (ru) | ||
| JP2018512041A5 (ru) | ||
| RU2018113709A (ru) | Модуляторы экспрессии kras | |
| EA201791820A1 (ru) | Олигонуклеотидная терапия врожденного амавроза лебера | |
| EP4372091A3 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| PH12018500145A1 (en) | Oligonucleotide compositions and methods thereof | |
| MX2024000277A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| EA201100812A1 (ru) | Фармацевтическая композиция | |
| WO2016106406A3 (en) | Rna agents for gst-pi gene modulation | |
| Wang et al. | MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF | |
| Di Leva et al. | MicroRNA in cancer: new hopes for antineoplastic chemotherapy | |
| WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
| CY1116876T1 (el) | Ολιγονουκλεοτιδικα αναλογα που ενσωματωνουν 5-αζα-κυτοσινη σε αυτα | |
| JP2012228254A5 (ru) | ||
| JP2014527401A5 (ru) | ||
| BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| JP2015507625A5 (ru) | ||
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| PH12014502569A1 (en) | Method for treating non-small cell lung cancer | |
| WO2011142798A3 (en) | Methods of preparing targeted aptamer prodrugs | |
| WO2018152524A1 (en) | Toxic rnai active seed sequences for killing cancer cells | |
| JP6137484B2 (ja) | 遺伝子発現抑制用二本鎖核酸分子 | |
| RU2016131028A (ru) | Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения |